11 – 20 of 120
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
Predictors of Secukinumab Treatment Response and Continuation in Axial Spondyloarthritis : Results From the EuroSpA Research Collaboration Network
- Contribution to journal › Article
-
Mark
Sex differences in patient-reported outcome measures and the association with clinical factors in axial spondyloarthritis patients treated with tumour necrosis factor inhibitors
- Contribution to journal › Article
-
Mark
Validity and reliability of the Danish and Swedish versions of the Bristol Rheumatoid Arthritis Fatigue Questionnaires in patients with spondyloarthritis
- Contribution to journal › Article
-
Mark
Vaccine Knowledge and Awareness Among Patients With Chronic Inflammatory Diseases : Results From a Nordic Survey
- Contribution to journal › Article
-
Mark
Differences in the response to TNF inhibitors at distinct joint locations in patients with psoriatic arthritis : results from nine European registries
- Contribution to journal › Article
-
Mark
Work loss in patients with rheumatoid arthritis treated with abatacept, rituximab, tocilizumab or TNF inhibitors : a nationwide direct drug-to-drug comparison
- Contribution to journal › Article
-
Mark
Increased prevalence of osteopenia and osteoporosis in systemic sclerosis patients, including in men and young women—a case–control study
- Contribution to journal › Article
-
Mark
Four-year secukinumab treatment outcomes in European real-world patients with axial spondyloarthritis and psoriatic arthritis
- Contribution to journal › Article
-
Mark
Handling of missing component information for common composite score outcomes used in axial spondyloarthritis research when complete-case analysis is unbiased
- Contribution to journal › Article
-
Mark
Musculoskeletal diseases, infections and vaccines : state of the art, research perspectives and educational needs
- Contribution to journal › Scientific review
